HWP
VRTX icon

Highline Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Highline Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$864K Buy
1,739
+1,417
+440% +$628K 0.18% 60
2026
Q1 		$144K Buy
322
+297
+1,188% +$138K 0.04% 100
2025
Q4 		$11.3K Sell
25
-13
-34% -$5.6K ﹤0.01% 371
2025
Q3 		$14.9K Sell
38
-5
-12% -$2.09K ﹤0.01% 337
2025
Q2 		$19.1K Buy
43
+1
+2% +$461 0.01% 231
2025
Q1 		$20.4K Buy
42
+26
+163% +$12.1K 0.01% 204
2024
Q4 		$6.44K Sell
16
-43
-73% -$19.9K ﹤0.01% 300
2024
Q3 		$27.4K Buy
59
+48
+436% +$23.1K 0.01% 162
2024
Q2 		$5.16K Buy
11
+1
+10% +$434 ﹤0.01% 289
2024
Q1 		$4.18K Hold
10
– – ﹤0.01% 285
2023
Q4 		$4.07K Hold
10
– – ﹤0.01% 256
2023
Q3 		$3.48K Hold
10
– – ﹤0.01% 243
2023
Q2 		$3.52K Hold
10
– – ﹤0.01% 194
2023
Q1 		$3.15K Hold
10
– – ﹤0.01% 204
2022
Q4 		$2.89K Hold
10
– – ﹤0.01% 198
2022
Q3 		$2.9K Buy
+10
New +$2.88K ﹤0.01% 191

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
MLL
Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM

Highline Wealth Partners's VRTX Position: Q2 2026 in Review

Highline Wealth Partners increased its Vertex Pharmaceuticals (VRTX) stake by 440% in Q2 2026, buying an estimated $628K and bringing the position to 1,739 shares worth $864K. The position accounts for 0.18% of the portfolio, ranked #60.

Highline Wealth Partners first reported a position in VRTX in Q3 2022 and has held it in 16 quarters since. 268 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Highline Wealth Partners held 1,739 shares of Vertex Pharmaceuticals worth $864K as of Q2 2026.
  • Highline Wealth Partners bought 1,417 Vertex Pharmaceuticals shares in Q2 2026, an estimated $628K.
  • Vertex Pharmaceuticals made up 0.18% of Highline Wealth Partners's portfolio in Q2 2026, its #60 holding.
  • Highline Wealth Partners first reported a position in Vertex Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • 268 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Highline Wealth Partners's 13F filing for Q2 2026, filed 15 Jul 2026.